Humedix Co Ltd
KOSDAQ:200670
Net Margin
Humedix Co Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| KR |
H
|
Humedix Co Ltd
KOSDAQ:200670
|
680.7B KRW |
27%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
722.7B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
401.4B USD |
25%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
205.1B CHF |
14%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
175.5B GBP |
15%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
182.6B CHF |
25%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
35%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
200.6B USD |
26%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
135B USD |
13%
|
Humedix Co Ltd
Glance View
Humedix Co., Ltd. engages in the manufacture and sale of hyaluronic acid based medical devices and arthritis treatment products. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2014-12-26. The firm distributes its products within domestic market and to overseas markets
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Humedix Co Ltd's most recent financial statements, the company has Net Margin of 27%.
You don't have any saved screeners yet